Guide to Federal Technology Transfer in Maryland
Maryland Department of Economic Development
2021 Jul
|
 |
OSA/NCATS Workshop: Expectations and Impact of TT |
 |
OSA/NCATS Workshop: Innovation In and Measuring TT |
 |
The U.S. National Institutes of Health – Founding A National Biomedical “Innovation Ecosystem”
Steven M. Ferguson and Lynn Johnson Langer
J Commer Biotechnol. 2021 Mar; 26(1): 72–82.
|
 |
Licensing the Technology: Biotechnology Commercialization Strategies Using University and Federal Labs (2nd Edition)
Steven M. Ferguson and Uma S. Kaundinya
In: Craig Shimasaki, ed. Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. (Elsevier Inc.) 2020:199-222. |
 |
I-Corps at NIH: Entrepreneurial Training Program Creating Successful Small Businesses
Christie A Canaria, Lili Portilla, Michael Weingarten Clin Transl Sci. 2019 Jul;12(4):324-328 |
 |
Intellectual Property and Technology Transfer
Bruce Goldstein
In: JI Gallin, FP Ognibene, LL Johnson, eds. Principles and Practice of Clinical Research (Fourth Edition). (Academic Press/Elsevier Inc.) 2017:447–529. |
 |
A Guide to Time Lag and Time Lag Shortening Strategies in Oncology-Based Drug Development
Berna Uygur, Josh Duberman, and Steven M. Ferguson J Commer Biotechnol. 2017 May;23(2):75-81. |
 |
Beyond Hybrid Licenses—Strategies for Post Patent Expiration Payments in the United States
Patrick Gattari, Steven Ferguson, David Crichton, and Bryan Helwig les Nouvelles. 2017 Mar;52(1):31-6. |
 |
How SBIR and STTR Can Support Women in Biotech Funding for Innovation from NIH’s Small Business Programs
Interview with Lili Portilla
In: Association for Women in Science, 2017;49:36-27 |
 |
The Commercialization of New Drugs and Vaccines Discovered in Public Sector Research
Stevens, A.J., Jensen, J.J., Wyller, K., Kilgore, P.C., London, E., Zhang, Q., Chatterjee, S., and Rohrbaugh, M.L,
In: S.M. Breznitz and H. Etzkowitz, eds., Routledge, University Technology Transfer: The Globalization of Academic Innovation, 2016:102-145 |
 |
NIH Inventions Translate into Drugs and Biologics with High Public Health Impact
Sabarni K. Chatterjee and Mark L. Rohrbaugh Nat Biotechnol. 2014 Jan 9;32(1):52-58. |
 |
Collaborative Development of 2-hydroxypropyl-β-cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease
Lili Portilla Curr Top Med Chem. 2014;14(3):330-339 |
 |
Leveraging Public Private Partnerships to Innovate Under Challenging Budget Times
Lili Portilla and Mark L. Rohrbaugh Curr Top Med Chem. 2014;14(3):326-329 |
 |
If The Sky Were The Limit, What Would You Do In Technology Transfer?
Gary Keller, Fizie Haleem, Steven Ferguson, Al Jordan, and Cheryl Cejka les Nouvelles. 2013 Mar;47(1):66-70. |
 |
Leveraging Public Private Partnerships to Innovate Under Challenging Budget Times
Portilla, L.M. and Rohrbaugh, M.L. Current Topics in Med. Chem., 2014;14(3):326-329 |
 |
Intellectual Property Claims to Stem Cell Technologies: Research Clinical Testing and Product Sales
Hammersla, A.M. and Rohrbaugh, M.L.,
In: Progenitor and Stem Cell Technologies and Therapies, A. Atala, ed., Woodhead Publishing Ltd. 2012 |
 |
Stem Cell Patents: What Every Researcher Should Know
Mark L. Rohrbaugh
In: Human Stem Cell Manual: A Laboratory Guide, JF Loring, SE Peterson, eds., Elsevier Press 2012;2 |
 |
Partnering with the NIH: Now part of the "Value Proposition" for start-ups
Steven M. Ferguson J Commer Biotechnol. 2012 Apr 1;18(2):60-67. |
 |
License Compliance Issues for Biopharmaceuticals: Special Challenges for Negotiations between Companies and Non-Profit Research Institutions
Todd A. Ponzio, Hans Feindt, and Steven M. Ferguson les Nouvelles, 2011 Sep;46(3):216-25. |
 |
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
Ashley J. Stevens, Jonathan J. Jensen, Katrine Wyller, Patrick C. Kilgore, Sabarni Chatterjee, and Mark L. Rohrbaugh N Engl J Med. 2011 Feb 10;364(6):535-41. |
 |